PROMISE of low-cost immunosuppressants for myasthenia gravis

Lancet Neurol. 2024 Mar;23(3):223-225. doi: 10.1016/S1474-4422(24)00034-6.

Authors

Sithara Ramdas¹, Jacqueline Palace²

Affiliations

¹ Department of Paediatric Neurology, John Radcliffe Hospital, Oxford, UK; MDUK Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford UK. Electronic address: sithara.ramdas@ouh.nhs.uk.
² Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.

PMID: 38365362
DOI: 10.1016/S1474-4422(24)00034-6

No abstract available

MeSH terms

Humans
Immunosuppressive Agents* / therapeutic use
Myasthenia Gravis* / drug therapy

Substances

Immunosuppressive Agents